2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)

2/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系（教育核心）

基本信息

批准号：
10006586
负责人：
Maurizio Pellecchia
金额：
$ 3.56万
依托单位：
UNIVERSITY OF CALIFORNIA RIVERSIDE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-02 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10006586
关键词：
African American American Antineoplastic Agents Applications Grants Award Basic Science Bioinformatics Biology California City of Hope Comprehensive Cancer Center Clinical Clinical Trials Collaborations Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility Data Drug Design Drug Targeting Eating Education Education and Outreach Educational Curriculum Engineering Ethics European Exposure to Faculty Funding Goals Health Sciences Hispanic Americans Hispanic-serving Institution Inequality Institution Investments Joints Laboratories Latino Master&apos s Degree Medical Students Mentorship Methods NCI Center for Cancer Research Participant Patients Persons Pharmaceutical Preparations Phase Phase I Clinical Trials Phase II Clinical Trials Physicians Precision Medicine Initiative Reporting Research Research Infrastructure Research Personnel Resources Rotation Running Scientist Societies Students System Testing Therapeutic Clinical Trial Training Training Programs Translating United States United States Food and Drug Administration United States National Institutes of Health Universities Visit anticancer research cancer health disparity career chimeric antigen receptor T cells clinical translation community clinic community partnership curriculum development drug development drug discovery education research education resources ethnic diversity experience first-in-human graduate student health disparity innovation manufacturing facility medical schools minority communities nanotherapy news next generation novel therapeutics outreach precision drugs precision medicine programs research and development screening social determinants stem cell therapy success summer research targeted agent undergraduate student virtual

项目摘要

Abstract: University of California at Riverside (UCR) is the newest medical school in the University of California system and a NIH-designated ISUPS institution. UCR's mandate is to serve SoCal's majority-minority communities and train the next generation of Latino/Hispanic-American and Black/African-American engineers, biologists, and physicians. City of Hope Comprehensive Cancer Center (CoH-CCC) is a Comprehensive Cancer Center whose 121 researchers have been awarded over $75M in NIH/NCI funding. CoH-CCC leads the world in academic drug discovery and has commercialized blockbusters drugs such as HumalinTM, HerceptinTM, and RituximabTM. CoH has world-class bioinformatics for drug design, extensive screening and synthetic capability, three onsite GMP-manufacturing facilities, and a robust clinical/translation Phase I program. Over the past 5 years 21 drugs have gone from R01 concept to first-in-man testing. The goal of the Collaborative Cancer Research Education Program (C-REP) is for UCR and CoH-CCC to develop the research experiences, curriculum, and outreach education resources necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. Aim 1: Research Experiences will provide tailored research experiences in cancer research and drug development. Aim 2: Curriculum Development will provide courses to introduce both UCR and CoH students and faculty to methods and innovation in drug development and the health science of disparities. Aim 3 Outreach Education and Resources will 1) expose early stage investigators to career opportunities drug development and clinical trials and 2) provide training and capacity building for fellows and faculty to translate their findings to drive drug discovery.

抽象的：加州大学河滨分校 (UCR) 是加州大学系统中最新的医学院以及 NIH 指定的 ISUPS 机构。 UCR 的使命是为南加州的多数少数族裔社区提供服务并培训下一代拉丁裔/西班牙裔美国人和黑人/非裔美国人工程师、生物学家、和医生。 City of Hope 综合癌症中心 (CoH-CCC) 是一家综合癌症中心其 121 名研究人员获得了 NIH/NCI 超过 7500 万美元的资助。 CoH-CCC 在以下方面处于世界领先地位学术药物发现并将重磅药物商业化，如 HumalinTM、HerceptinTM 和利妥昔单抗TM。 CoH 拥有世界一流的药物设计生物信息学、广泛的筛选和合成能力，三个现场 GMP 生产设施，以及强大的临床/转化一期计划。过去 5 21年药物已经从R01概念进入首次人体测试。合作癌症研究教育计划 (C-REP) 的目标是针对 UCR 和 CoH-CCC 开发必要的研究经验、课程和外展教育资源，以发展反映南加州内陆种族多样性的下一代治疗研究人员。目的 1：研究经验将提供癌症研究和药物方面的定制研究经验发展。目标 2：课程开发将提供课程来介绍 UCR 和 CoH 学生以及药物开发和健康科学差异方面的方法和创新的教师。目标 3 外展教育和资源将 1) 让早期研究人员接触毒品的职业机会开发和临床试验，2) 为研究员和教员提供翻译培训和能力建设他们的发现推动了药物发现。